BLA 125554 · Bristol Myers Squibb
Opdivo
Nivolumab · Injection · Programmed Death Receptor-1 Blocking Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 22, 2014
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
1,779
188 Phase 3, 304 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Nivolumab" as an intervention, any sponsor and status, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyPivotal-lookingEnrolling by invitation
ExelixisIndustry
NCT07620574 · 5,000 participants (planned) · Start Jul 30, 2026 · Primary completion May 31, 2030
Drug: Cabozantinib; Zanzalintinib and 5 more · For: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) and 6 more
Sites: Bay Shore, New York; Kettering, Ohio; Memphis, Tennessee · 4 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07431281 · 2,130 participants (planned) · Start Feb 3, 2026 · Primary completion Aug 16, 2029
Drug: Sonesitatug vedotin; Rilvegostomig and 6 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 314 sites in all
- Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02872116 · 2,031 participants · Start Oct 12, 2016 · Primary completion May 27, 2020
Drug: Nivolumab; Ipilimumab and 4 more · For: Gastric Cancer; Gastroesophageal Junction Cancer; Esophageal Adenocarcinoma
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 179 sites in all
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Opdivo (Nivolumab)
2024 spending
$50.3M
Beneficiaries
690
4,120 claims
Per beneficiary
$72,883
$308.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,098,263 |
| 2021 | $33,651,451 |
| 2022 | $43,848,492 |
| 2023 | $51,314,795 |
| 2024 | $50,289,570 |
Part B: Opdivo (Nivolumab) · HCPCS J9299
2024 spending
$1.93B
Beneficiaries
26,951
176,422 claims
Per beneficiary
$71,752
2024 ASP limit $31.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,586,651,124 |
| 2021 | $1,573,611,853 |
| 2022 | $1,849,938,540 |
| 2023 | $1,910,233,910 |
| 2024 | $1,933,800,338 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Blank CU, Lucas MW, Scolyer RA, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY, Shitara K, Moehler M, et al. · Lancet 2021 · Clinical Trial, Phase III, Comparative Study
- Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.